Wockhardt Files EMA Application for Novel Antibiotic WCK 5222

13 Jan 2026 CW Team

Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222, marking a significant milestone in the company’s global regulatory journey. The application was submitted on January 5, 2026, positioning the drug for scientific evaluation across 27 European Union member states and three European Economic Area countries—Norway, Iceland and Liechtenstein—covering a total of 30 nations.

The EMA, which is responsible for the centralised assessment of new medicines in Europe, had earlier informed Wockhardt that WCK 5222 qualifies for the Accelerated Assessment pathway. This provision enables a shortened review timeline for therapies that address serious unmet medical needs, underlining the clinical importance of the antibiotic in combating resistant infections.

WCK 5222 is a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), developed to treat severe Gram-negative bacterial infections that are resistant to existing therapies. The product is already under fast-track review by the US Food and Drug Administration, reflecting growing global regulatory recognition of its potential clinical value.

Based on the clinical and regulatory data submitted, Wockhardt anticipates approval of WCK 5222 for the treatment of multidrug-resistant Gram-negative infections across all countries under the EMA’s jurisdiction. The priority status accorded to the application highlights the urgent global need for effective treatment options for patients suffering from life-threatening infections caused by antimicrobial resistance.

Notably, WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation, reinforcing India’s growing capabilities in advanced pharmaceutical research and innovation.

Real Estate

28 Feb 2026

Casagrand Launches Keystone In Tiruppur

Casagrand has launched Casagrand Keystone, a gated residential development at Rakkiyapalayam, off Avinashi Road, in Tiruppur. Spread across 2.2 acres, the B+G+5 structure comprises 142 units of 2 and 3 BHK homes, supported by 48 indoor and outdoor amenities. The project is introduced at a starting price of Rs 5,199 per sq. ft. The development allocates 1.3 acres to open space, including a central park of about 24,500 sq. ft. A 6,800 sq. ft. clubhouse includes a multipurpose hall, mini theatre and indoor recreation facilities. Other amenities include a 5,100 sq. ft. swimming pool, poolside par..

Premium homes account for half of India’s housing sales in 2025

Knight Frank India, in its latest report on India’s office and residential property market, has highlighted a significant shift in housing demand, with homes priced above Rs 10 million accounting for 50 per cent of total residential sales across the top eight cities in 2025. The findings underscore the growing dominance of premium housing in the country’s real estate landscape.Out of 348,247 residential units sold during the year, approximately 175,091 units were in the Rs 10 million-plus category, marking a 14 per cent year-on-year increase. The data reflects changing buyer preferences, w..

Xbattery launches XB-5K energy storage system for homes, offices

Xbattery, a Hyderabad-based deep-tech company specialising in next-generation energy storage and battery management technologies, has introduced its flagship XB-5K, a scalable 5kWh energy storage system designed for homes and offices in India.The XB-5K is built on the company’s indigenously developed BharatBMS platform, described as India’s first universal high-voltage battery management system architecture aimed at reducing import dependence and improving after-sales service capabilities. The launch comes as India seeks to strengthen domestic manufacturing and address reliance on imported..